beta-alanine has been researched along with Colorectal Cancer in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the relationship between systemic exposure to capecitabine metabolites and parameters of efficacy and safety in patients with advanced or metastatic colorectal cancer from two phase III studies." | 9.10 | Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. ( Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003) |
| "High-dose 5-fluorouracil (5-FU) containing chemotherapy occasionally causes hyperammonemia and can be lethal." | 7.85 | Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. ( Funakoshi, T; Horimatsu, T; Matsubara, K; Matsubara, T; Miyamoto, S; Muto, M; Nakagawa, S; Nishikawa, Y; Yanagita, M; Yonezawa, A, 2017) |
| "To assess the relationship between systemic exposure to capecitabine metabolites and parameters of efficacy and safety in patients with advanced or metastatic colorectal cancer from two phase III studies." | 5.10 | Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. ( Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003) |
| "High-dose 5-fluorouracil (5-FU) containing chemotherapy occasionally causes hyperammonemia and can be lethal." | 3.85 | Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. ( Funakoshi, T; Horimatsu, T; Matsubara, K; Matsubara, T; Miyamoto, S; Muto, M; Nakagawa, S; Nishikawa, Y; Yanagita, M; Yonezawa, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishikawa, Y | 1 |
| Funakoshi, T | 1 |
| Horimatsu, T | 1 |
| Miyamoto, S | 1 |
| Matsubara, T | 1 |
| Yanagita, M | 1 |
| Nakagawa, S | 1 |
| Yonezawa, A | 1 |
| Matsubara, K | 1 |
| Muto, M | 1 |
| Gieschke, R | 1 |
| Burger, HU | 1 |
| Reigner, B | 1 |
| Blesch, KS | 1 |
| Steimer, JL | 1 |
| Van Kuilenburg, AB | 1 |
| Poorter, RL | 1 |
| Peters, GJ | 1 |
| Van Gennip, AH | 1 |
| Van Lenthe, H | 1 |
| Stroomer, AE | 1 |
| Smid, K | 1 |
| Noordhuis, P | 1 |
| Bakker, PJ | 1 |
| Veenhof, CH | 1 |
| Cao, S | 1 |
| Baccanari, DP | 1 |
| Rustum, YM | 1 |
| Davis, ST | 1 |
| Tansik, RL | 1 |
| Porter, DJ | 1 |
| Spector, T | 1 |
| Pawlik, TM | 1 |
| Souba, WW | 1 |
| Sweeney, TJ | 1 |
| Bode, BP | 1 |
1 trial available for beta-alanine and Colorectal Cancer
| Article | Year |
|---|---|
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2003 |
4 other studies available for beta-alanine and Colorectal Cancer
| Article | Year |
|---|---|
Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.
Topics: Aged; Ammonia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta | 2017 |
No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; beta-Alanine; Circadian Rhythm; Colorectal Neoplasms; Dihydrouracil | 1998 |
alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; beta-Alanine; Colonic Neoplasms; Colorectal Neoplasms; Dru | 2000 |
Phorbol esters rapidly attenuate glutamine uptake and growth in human colon carcinoma cells.
Topics: Arginine; beta-Alanine; Biological Transport; Carcinogens; Cell Division; Colorectal Neoplasms; Glut | 2000 |